Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Barhemsys
Synonyms :
Class :
Antiemetics, Atypical antipsychotics
Brand Name :
Barhemsys
Synonyms :
Class :
Antiemetics, Atypical antipsychotics
Dosage Forms & Strengths
Injectable solution
2.5mg/mL (2 mL/4 mL) -single-dose vial
Prevention: 5 mg IV over 1-2 minutes at time of anesthesia induction
Treatment: 10 mg IV over 1 to 2 minutes postoperatively
Safety and efficacy not established
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
It may enhance toxicity when combined with perphenazine
amisulpride: they may increase the CNS depressant effect of CNS Depressants
amisulpride: they may increase the CNS depressant effect of CNS Depressants
amisulpride: they may increase the CNS depressant effect of CNS Depressants
amisulpride: they may increase the CNS depressant effect of CNS Depressants
amisulpride: they may increase the CNS depressant effect of CNS Depressants
when both drugs are combined, there may be an increase in qtc interval
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
It may enhance the toxicity effect when combined with lumateperone
administration of rotigotine along with amisulpride reduces the activity of each other due to antagonism
Dopamine agonists like rotigotine should not be given with dopamine antagonists like amisulpride
It may enhance sedation when combined with tramadol
it decreases the efficacy of anti parkinsonism agents
It may enhance sedation when combined with oxycodone
It may enhance QTc interval when combined with lithium
it may enhance the qtc interval when combined with lofexidine
amisulpiride: they may increase the toxic effect of antipsychotic agents
amisulpiride: they may increase the toxic effect of antipsychotic agents
amisulpiride: they may increase the toxic effect of antipsychotic agents
amisulpiride: they may increase the toxic effect of antipsychotic agents
amisulpiride: they may increase the toxic effect of antipsychotic agents
the efficacy of Dopamine agonists will be decreased when amisulpride is used in combination
the efficacy of Dopamine agonists will be decreased when amisulpride is used in combination
the efficacy of Dopamine agonists will be decreased when amisulpride is used in combination
the efficacy of Dopamine agonists will be decreased when amisulpride is used in combination
the efficacy of Dopamine agonists will be decreased when amisulpride is used in combination
QTc interval increases on taking amisulpride and lenvatinib together. Avoid or take an alternate drug
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
both lapatinib and amisulpride increase the QTc level
may increase the QT-prolonging effect and enhance the risk of ventricular arrhythmias
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be increase in both increase QTc interval
when both drugs are combined, there may be increase in both increase QTc interval
may increase the QTc interval
glycopyrrolate inhaled and formoterol
may increase the QTc interval when combined
may decrease the therapeutic effect of cabergoline
may decrease the therapeutic effect of anti-Parkinson agents
It may enhance QTc interval when combined with pentamidine
may increase the toxic effect of Antipsychotic Agents
It may enhance sedation when combined with codeine
may have an increased effect of CNS depression when combined with Amisulpride
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may reduce the therapeutic effect of anti-parkinson agents
may reduce the therapeutic effect of anti-parkinson agents
may reduce the therapeutic effect of anti-parkinson agents
may reduce the therapeutic effect of anti-parkinson agents
may reduce the therapeutic effect of anti-parkinson agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
It may enhance sedation when combined with phenobarbital
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
It may enhance the sedation effect when combined with lumateperone
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
It may enhance the sedation when combined with tasimelteon
ajmaline enhances the risk of QTc prolongation when combined with amisulpride
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
The potential for QTc prolongation's risk or seriousness may escalate with the concomitant use of mibefradil and amisulpride
The potential for increased CNS depression risk or seriousness occurs when amisulpride is used together with pinazepam
When amisulpride is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with amisulpride, There is a risk or seriousness of CNS depression is enhanced
When amisulpride is used together with medazepam, the risk or seriousness of CNS depression is enhanced
amisulpride may intensify paraldehyde's CNS depressant effects
When amisulpride is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When chlordiazepoxide is used together with amisulpride, this leads to enhanced risk or seriousness of CNS depression
When amisulpride is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
When ponesimod is used together with amisulpride, this leads to enhanced risk or seriousness of bradycardia
When amisulpride is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When amisulpride is used together with givinostat, this leads to enhanced risk or severity of Qtc prolongation
When emylcamate is used together with amisulpride, this leads to enhanced risk or seriousness of CNS depression
When amisulpride is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
the therapeutic efficacy of insulin pork can be lowered when used in combination with amisulpride
it may increase the QT-c prolonging effect of QT-prolonging agents such as toremifene
it increases the QT-c prolonging effect of gilteritinib
it increases the QTc prolongation of ondansetron
it increases the QTc prolongation of ondansetron
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may decrease the absorption of antipsychotic agents
may increase the hypotensive effect of antihypertensives
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may increase the Qtc prolonging effect
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may increase the QTc-prolonging effect of QT-prolonging Agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the hypotensive effect of Hypotension-Associated Agents
It may enhance the risk of adverse reactions when combined with Enzymes
choline magnesium trisalicylate
It may enhance the risk of adverse reactions when combined with Salicylates
the risk of CNS depression may be increased
When amisulpride is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Adverse drug reactions:
Frequency Defined
1-10%
Chills
Hypokalemia
Procedural hypotension
Increased blood prolactin
Abdominal distension
Infusion site pain
Post marketing Reports
Agranulocytosis
Bradycardia
torsades de pointes
ventricular tachycardia
prolonged QT by ECG
Pregnancy warnings:
Pregnancy Category: N/A
Breastfeeding warnings:
crosses into breast milk- known
Pregnancy Categories:
Patient Information Leaflet
Generic Name: amisulpride
Why do we use amisulpride?
amisulpride belongs to the class of Antiemetic Agents, which helps in treating Postoperative Nausea & Vomiting.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
